Possible scenario
Commercial AI Biology
25% Chance
The atlas becomes an input for commercial AI-biology tools that prioritize microproteins as drug targets or biomarkers. This would fit the recent pattern of open datasets accelerating private model development rather than remaining purely academic infrastructure.
Secondary impacts
- Healthcare +0.4%
- Technology +0.2%
Tickers
- RXRX+1.0%
- SDGR+0.4%
Portfolio impact
S&P 500+0.1%
Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.
Keeping an eye on this scenario?
Tilt can alert you when its probability or impact shifts, or send you a recommendation when it crosses a threshold.